A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment with Adalimumab and MTX

Trial Profile

A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment with Adalimumab and MTX

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Sarilumab (Primary) ; Adalimumab; Etanercept; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms RA-COMPARE; SARIL-RA-COMPARE
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Feb 2015 Status changed from recruiting to discontinued according to ClinicalTrials.gov.
    • 04 Feb 2015 Planned End Date changed from 1 Jan 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top